RT Journal Article
SR Electronic
T1 Muscle Strength and Muscle Mass as Predictors of Hospital Length of Stay in Patients with Moderate to Severe COVID-19: A Prospective Observational Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.30.21254578
DO 10.1101/2021.03.30.21254578
A1 Gil, Saulo
A1 Filho, Wilson Jacob
A1 Shinjo, Samuel Katsuyuki
A1 Ferriolli, Eduardo
A1 Busse, Alexandre Leopold
A1 Avelino-Silva, Thiago Junqueira
A1 Longobardi, Igor
A1 de Oliveira, Gersiel Nascimento
A1 Swinton, Paul
A1 Gualano, Bruno
A1 Roschel, Hamilton
A1 ,
A1 Bonfá, Eloisa
A1 Utiyama, Edivaldo
A1 Segurado, Aluisio
A1 Perondi, Beatriz
A1 Morais, Anna Miethke
A1 Montal, Amanda
A1 Letaif, Leila
A1 Fusco, Solange
A1 da Silva, Marjorie Fregonesi Rodrigues
A1 Rocha, Marcelo
A1 Marcilio, Izabel
A1 Rios, Izabel Cristina
A1 Kawano, Fabiane Yumi Ogihara
A1 Amélia de Jesus, Maria
A1 Kallas, Ésper Georges
A1 Carmo, Carolina
A1 Tanaka, Clarice
A1 de Souza, Heraldo Possolo
A1 Marchini, Julio F. M.
A1 Carvalho, Carlos
A1 Ferreira, Juliana Carvalho
A1 Levin, Anna Sara Shafferman
A1 de Oliveira, Maura Salaroli
A1 Guimarães, Thaís
A1 Lázari, Carolina dos Santos
A1 José da Silva Duarte, Alberto
A1 Sabino, Ester
A1 Magri, Marcello Mihailenko Chaves
A1 Barros-Filho, Tarcisio E. P.
A1 Francisco, Maria Cristina Peres Braido
YR 2021
UL http://medrxiv.org/content/early/2021/03/31/2021.03.30.21254578.abstract
AB Importance Strength and muscle mass are predictors of relevant clinical outcomes in critically ill patients, but in hospitalized patients with COVID-19 remains to be determined.Objective To investigate whether muscle strength or muscle mass are predictive of hospital length of stay (LOS) in patients with moderate to severe COVID-19.Design Prospective observational study.Setting Clinical Hospital of the School of Medicine of the University of Sao Paulo.Participants One hundred ninety-six patients were evaluated. Ten patients did not test positive for SARS-CoV-2 during hospitalization and were excluded from the analyses. The sample comprised patients of both sexes (50% male) with a mean age (SD) of 59 (±15) years, body mass index of 29.5 (±6.9) kg/m2. The prevalence of current smoking patients was 24.7%, and more prevalent coexisting conditions were hypertension (67.7%), obesity (40.9%), and type 2 diabetes (36.0%). Mean (SD) LOS was 8.6 days (7.7); 17.0% of the patients required intensive care; 3.8% used invasive mechanical ventilation; and 6.6% died during the hospitalization period.Main outcome The outcome was LOS, defined as time from hospital admission to medical discharge.Results The crude Hazard Ratio (HR) for LOS was greatest for handgrip strength comparing the strongest vs. other patients (1.54 [95%CI: 1.12 – 2.12; p = 0.008]). Evidence of an association between increased handgrip strength and shorter hospital stay was also identified when handgrip strength was standardized according to the sex-specific mean and standard deviation (1.23 [95%CI: 1.06 – 1.19; p = 0.008]). The magnitude of these associations remained consistent and statistically significant after adjusting for other covariates. Mean LOS was shorter for the strongest patients (7.5 ± 6.1 days) vs. others (9.2 ± 8.4 days). Evidence of associations were also present for vastus lateralis cross-sectional area. The crude HR identified shorter hospital stay for patients with greater sex-specific standardized values (1.17 [95%CI: 1.01 – 1.36; p = 0.037]); however, we found increased uncertainty in the estimate with the addition of other covariates (1.18 [95%CI: 0.97 – 1.43; p = 0.092]). Evidence was also obtained associating longer hospital stays for patients with the lowest values for vastus lateralis cross-sectional area (0.69 [95%CI: 0.50 – 0.95; p = 0.025). Mean LOS for the patients with the lowest muscle cross-sectional area was longer (10.8 ± 8.8 days) vs. others (7.7 ± 7.2 days).Conclusions and Relevance Muscle strength and mass assessed upon hospital admission are predictors of LOS in patients with moderate to severe COVID-19, which stresses the value of muscle health in prognosis of this disease.Funding The authors acknowledge the support by the Brazilian National Council for Scientific and Technological Development (CNPq - grant 301571/2017-1). H.R. and B.G. are supported by grants from the Conselho Nacional de Pesquisa e Desenvolvimento (CNPq 428242/2018-9; 301571/2017-1; 301914/2017-6). B.G. is also supported by a grant from the Sao Paulo Research Foundation (FAPESP 2017/13552-2).Question Do muscle strength and muscle mass predict hospital length of stay (LOS) in patients with moderate to severe COVID-19 patients?Findings In this prospective observational study that included 186 hospitalized patients with moderate to severe COVID-19, we observed that LOS was shorter among patients in the highest tertile of strength (assessed by handgrip) vs. those in the mid/lowest tertiles (crude Hazard Ratio [HR]: 1.54, 95%CI: 1.12-2.12). In addition, LOS was longer among patients in the lowest tertile of muscle cross-sectional area (assessed by ultrasound imaging) vs. those in the mid/highest tertiles (HR: 0.69, 95%CI: 0.50 – 0.95).Meaning Muscle strength and mass assessed on hospital admission are predictors of LOS in patients with moderate to severe COVID-19, suggesting that muscle health may be protective in this disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of the Clinical Hospital of the School of Medicine of the University of Sao Paulo in Brazil (HCFMUSP) (Ethics Committee Approval Number: 31303720.7.0000.0068).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFurther information and requests for database should be directed to and will be fulfilled by the Lead Contact, Hamilton Roschel (hars{at}usp.br).